Slide 1: FY22 Annual Results Investor Presentation
FY22 Te Whakatakotoranga ki nga Kaiwhakangao o ngā Otinga ā Tau FY22 Annual Results Investor Presentation 30 August 2022
Slide 2: Disclaimer
Rua Bioscience Limited (Rua) is a New Zealand pharmaceutical company aiming to be a leading producer of cannabinoid derived medicines. This presentation and the information contained in or accompanying this presentation are not, and are under no circumstances to be construed as, an invitation to sub
Slide 3: Chief Executive Officer and Chief Financial Officer
Rob Mitchell Hamish White Kaiwhakahāere Matua Āpiha Kaiwhakahāere Pūtea Chief Executive Officer Chief Financial Officer 3
Slide 4: Managing Director and Executive Director, Co-Founder
Anna Stove Panapa Ehau Kaiwhakahāere Ringatohu Kaiwhakaū / Ringatohu Managing Director Executive Director, Co-Founder 4
Slide 5: Overview
• Operational Achievements Tirohanga Whānui • Key Appointments Overview • Financial Highlights • Outlook 5
Slide 6: FY22: An Overview
Tirohanga Whānui FY22: An Overview In FY22, Rua focused on preparing for market entry – securing the partners and developing the frameworks and strategies that will give the company the best chance of success both at home and abroad. By the close of FY22, Rua launched its first product in New Zealan
Slide 7: Achievements at a Glance
September 2021 Achieved GMP certification December 2021 Green light to distribute first product in New Zealand Welcomed the East Coast Cannabis Company (E3C). Mawhiti mai ki nga January 2022 Whakatutukitanga Shareholders approve Zalm Therapeutics acquisition Achievements at a Glance April 2022 First
Slide 8: Rua Launches First Product for New Zealand Patients
Te Whakaterenga o te Hua Tuatahi o Rua ki nga Tūroro kei Aotearoa Rua Launches First Product for New Zealand Patients The launch of Rua’s first medicine in Aotearoa was a milestone for New Zealand patients, prescribers, and the medicinal cannabis industry. Rua will launch a range of new medicines in
Slide 9: Rua Significantly Advances German Market Entry
Te Kōkiritanga a Rua ki te Mākete o Tiāmana Rua Significantly Advances German Market Entry In June, Rua received its narcotic license through Nimbus Health for the distribution and marketing of its first product for the German medicinal cannabis market – a move understood to make Rua the first medic
Slide 10: Developing Local Cultivation Capacity
Te Whakawhanake Whakatupu o te Kāinga Developing Local Cultivation Capacity Rua’s indoor cultivation team continues to establish the unique varieties which Rua will be able to grow at scale in Cann’s GMP-certified facility at Mildura . Rua also welcomed E3C as its first local cultivation partner in
Slide 11: Developing Production Capacity to Service Further Global Markets
Te Whakawhanake Huanga hei Ratonga ki ngā Mākete o te Ao Whānui Developing Production Capacity to Service Further Global Markets In January 2022, shareholders overwhelmingly approved the purchase of Zalm. Critical to the acquisition, Rua secured access to Zalm’s third-party supply contract for GMP-g
Slide 12: Investing in Innovation Across the Value Chain
Whakangao Developing atu ki Local nga Cultivation Capacity Kaupapa New Ruatorea, Hou Whai Hua Zealand Investing in Innovation Across the Value Chain Rua’s indoor cultivation team has focused on genetic export readiness by continuing to R&D is important for Rua as the company establish the commercial
Slide 13: Our People – World-class Capability
Te Whānau o Rua – Nga Toa Āheitanga o te Ao Our People – World-class Capability DR JACK CHAN DR SUSAN MARTINDALE AMY QUATTLEBAUM Production Manager Head of Regulatory Affairs, PhD Quality Control Analyst PhD in Pharmacy from the University of a lifetime of experience in regulatory Studied biochemist
Slide 14: Financial Highlights: Profit & Loss
Nga Pūtea Total income $646k Financial Highlights Profit & Loss Investment in R&D $2.98m Loss before tax for the year ended Rua’s annual financial results for the 30 June 2022 was $7.49m year the ended 30 June 2022. 14
Slide 15: Financial Highlights: Balance Sheet
Cash, Cash Equivalents and Investments Nga Pūtea $9.94m Financial Highlights Total Assets $33.57m Balance Sheet Total Liabilities $9.38m Rua’s annual financial results for the year the ended 30 June 2022. Net Assets of $24.2m 15
Slide 16: Financial Highlights: Cashflow
Nga Pūtea Net cash outflow from operating Financial Highlights activities $6.84m Cashflow Net cash inflow from investing activities $5.59m Rua’s annual financial results for the year the ended 30 June 2022. Net cash outflow from financing activities $209k 16
Slide 17: Outlook for the NZ Market
Te Tirohanga Whānui o te Mākete o Aotearoa Outlook for the NZ Market FY22 saw the realisation of commercialisation milestones for Rua with regulatory approvals enabling the production and subsequent New Zealand launch of Rua’s first product, a CBD oil. Rua will build on this success in FY23, increas
Slide 18: Outlook for Export Markets
Rua expects to enter the German market via its supply Te Tirohanga Whānui ki nga Mākete ki agreement with Nimbus Tāwāhi Health. Outlook for Export Markets Rua will explore business opportunities with parties in the Czech Republic, Poland and the United Kingdom. Rua expects to advance the five-year a
Slide 19: Join us for the AGM
Nau mai ki te hui ā Tau Join us for the AGM 10:00am 12 October, 2022 Waikanae Surf Club, Gisborne and online. 19
Slide 20: FY22 Annual Results
FY22 Te Whakatakotoranga ki nga Kaiwhakangao o ngā Otinga ā Tau FY22 Annual Results Investor Presentation 30 August 2022